SSR-180,711

Из Википедије, слободне енциклопедије
SSR-180,711
(IUPAC) ime
(4-bromofenil) 1,4-diazabiciklo[3.2.2]nonan-4-karboksilat
Klinički podaci
Identifikatori
ATC kod nije dodeljen
PubChem[1][2] 9928899
Hemijski podaci
Formula C14H21BrN2O2 
Mol. masa 329,232
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status

SSR-180,711 je lek koji deluje kao potentan i selektivan parcijalni agonist za α7 tip neuronskog nikotinskog acetilholinskog receptora.[3][4] U životinjskim studijama on je pokazao nutropne efekte, te potencijalno može da bude koristan u tretmanju šizofrenije.[5][6]

Reference[уреди]

  1. ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.“. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. ^ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities“. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. ^ Pichat, P.; Bergis, O.; Terranova, J.; Urani, A.; Duarte, C.; Santucci, V.; Gueudet, C.; Voltz, C. et al. (2007). „SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia“. Neuropsychopharmacology 32 (1): 17–34. DOI:10.1038/sj.npp.1301188. PMID 16936709. 
  4. ^ Biton, B.; Bergis, O.; Galli, F.; Nedelec, A.; Lochead, A.; Jegham, S.; Godet, D.; Lanneau, C. et al. (2007). „SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile“. Neuropsychopharmacology 32 (1): 1–16. DOI:10.1038/sj.npp.1301189. PMID 17019409. 
  5. ^ Hashimoto, K.; Ishima, T.; Fujita, Y.; Matsuo, M.; Kobashi, T.; Takahagi, M.; Tsukada, H.; Iyo, M. (2008). „Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711“. Biological Psychiatry 63 (1): 92–97. DOI:10.1016/j.biopsych.2007.04.034. PMID 17601496. 
  6. ^ Barak, S.; Arad, M.; De Levie, A.; Black, M.; Griebel, G.; Weiner, I. (2009). „Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia“. Neuropsychopharmacology 34 (7): 1753–1763. DOI:10.1038/npp.2008.232. PMID 19158670. 

Spoljašnje veze[уреди]